While repeat biopsies provide critical information, there are alternative methods for monitoring disease progression and treatment response. Non-invasive imaging techniques, such as MRI, CT scans, and PET scans, can offer valuable insights without the need for additional tissue sampling. Liquid biopsies, which analyze circulating tumor DNA (ctDNA) in the blood, are emerging as a promising alternative, especially for monitoring cancer. However, these methods may not always provide the same level of detail as histological examinations.
